Malleability of the SARS-CoV-2 3CL M(pro) Active-Site Cavity Facilitates Binding of Clinical Antivirals

The COVID-19 pandemic caused by SARS-CoV-2 requires rapid development of specific therapeutics and vaccines. The main protease of SARS-CoV-2, 3CL M(pro), is an established drug target for the design of inhibitors to stop the virus replication. Repurposing existing clinical drugs can offer a faster r...

Descripción completa

Detalles Bibliográficos
Autores principales: Kneller, Daniel W., Galanie, Stephanie, Phillips, Gwyndalyn, O'Neill, Hugh M., Coates, Leighton, Kovalevsky, Andrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2020
Materias:
Short Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584437/
https://www.ncbi.nlm.nih.gov/pubmed/33152262
http://dx.doi.org/10.1016/j.str.2020.10.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584437/
https://www.ncbi.nlm.nih.gov/pubmed/33152262
http://dx.doi.org/10.1016/j.str.2020.10.007

Ejemplares similares